Assist Prof Dr. Yasir Al-Mawlah | Cancer Genetics | Editorial Board Member

Researcher | University Of Babylon | Iraq

Yasir Haider Al-Mawlah is an accomplished oncology- and biotechnology-oriented researcher and academic based at the DNA Research Center, University of Babylon, Iraq, with a strong interdisciplinary background spanning molecular biology, biotechnology, forensic genetics, and cancer-related research. He holds a verified academic appointment at the University of Babylon and has established a solid scientific profile with more than 220 citations, an h-index of 9, and an i10-index of 8, reflecting consistent scholarly impact over several years. His oncology-related work focuses primarily on molecular mechanisms of cancer development, genetic susceptibility, and biomarker discovery, particularly in breast cancer. He has contributed significantly to studies examining genetic polymorphisms in antioxidant enzymes such as SOD, CAT, and GPx1 and their association with breast cancer risk, oxidative stress, and biomarker alterations, providing insights into cancer pathogenesis and potential diagnostic indicators. In addition, his research includes anti-cancer evaluations of natural compounds, such as plant-derived alkaloids, against human breast cancer cell lines, highlighting translational approaches that bridge natural product research and oncology therapeutics. Beyond cancer, his scientific contributions extend to microRNA expression profiling, including fertility, forensic identification, and body fluid differentiation, demonstrating advanced expertise in non-coding RNA stability and specificity. He has also published widely on antimicrobial nanoparticles, nanobiotechnology, and multidrug-resistant pathogens, reflecting a broader biomedical scope relevant to cancer-associated infections and clinical complications. Dr. Al-Mawlah collaborates extensively with multidisciplinary teams across medical microbiology, genetics, pharmacology, and clinical sciences, both within Iraq and internationally. His publication record in peer-reviewed journals, combined with sustained citation performance, underscores his role as an active contributor to contemporary biomedical and oncology-related research, with work that supports early diagnosis, molecular risk assessment, and innovative therapeutic exploration in cancer and related diseases.

Profile: Google Scholar

Featured Publications

Al-Mawlah, Y. H., Al-Darraji, M. N., & Al-Imari, M. J. (2022). Study of small non-coding RNA (miRNA) expression pattern of fertile/infertile male semen. Acta Informatica Medica, 30(3), 205–210.

Abdulazeem, L., Al-Alaq, F. T., Alrubaei, H. A., Al-Mawlah, Y. H., & Alwan, W. K. (2018). Anti-cancer activity of Opuntia polyacantha alkaloid extract on human breast cancer cell line. Journal of Pharmaceutical Sciences and Research, 10(7), 1753–1754.

Al-Mawlah, Y. H., Alasadi, Y. F., & Al-Darraji, M. N. (2021). Association between genetic polymorphisms of Cu/ZnSOD and CAT C262T and the risk of breast cancer. Gene Reports, 25, 101401.

Abdulazeem, L., Al-Amiedi, B. H., Alrubaei, H. A., & Al-Mawlah, Y. H. (2019). Titanium dioxide nanoparticles as antibacterial agents against some pathogenic bacteria. Drug Invention Today, 12(5), 963–967.

Al-Mawlah, Y. H., Naji, M. Z., Al-Imari, M. J., & Abdulabbas, H. S. (2022). Micro-RNA evaluation, specification, and stabilization study in mixed and non-mixed body fluids as a specific molecular marker. Journal of Advanced Biotechnology and Experimental Therapeutics, 5(2), 347–357.

Through integrative research in oncology, molecular genetics, and biotechnology, the nominee advances scientific understanding of cancer risk, biomarker discovery, and molecular diagnostics. His work bridges fundamental research with applied innovation, supporting early detection, personalized medicine, and translational solutions that benefit public health and biomedical development.

Dr. Ali Moradi Kalan | Cancer Genetics | Editorial Board Member

Doctor | Medical School Tabriz | Iran

Ali Moradi Kalan is an oncology and public health–focused researcher affiliated with Tabriz University of Medical Sciences, with a scholarly profile reflecting strong contributions to cancer epidemiology, disease burden analysis, and population health research. With 966 total citations and an h-index of 5, his work demonstrates consistent academic influence, particularly in large-scale epidemiologic assessments and region-specific cancer reviews. His most highly cited contribution is a landmark 2021 Lancet study examining spatial, temporal, and demographic patterns of tobacco smoking and its attributable disease burden across 204 countries from 1990 to 2019, a publication that has significantly informed global tobacco control policies and cancer prevention strategies. In addition to global health modeling, he has led and co-authored systematic and narrative reviews on major cancers in Iran, including gastric and bladder cancer, providing critical insights into incidence trends, risk factors, and public health implications within the regional context. His research portfolio also spans interdisciplinary biomedical themes, such as the role of environmental toxins like arsenic in neuroinflammatory mechanisms and molecular studies exploring immunomodulatory and gene expression effects of nutritional and hormonal compounds. Through these works, he bridges epidemiology, clinical oncology, and mechanistic research, emphasizing prevention, early detection, and evidence-based policy. His publications appear in reputable international journals including The Lancet, Clinical and Experimental Gastroenterology, Research and Reports in Urology, Nutritional Neuroscience, and Journal of Molecular Neuroscience, underscoring the translational relevance and scientific rigor of his scholarship. Collectively, Ali Moradi Kalan’s research advances understanding of cancer burden and modifiable risk factors at both global and national levels, supporting improved public health planning, targeted interventions, and future oncology research, while positioning him as a contributor to data-driven cancer epidemiology and population-based health sciences.

Profile: Google Scholar

Featured Publications

Reitsma, M. B., Kendrick, P. J., Ababneh, E., Abbafati, C., Abbasi-Kangevari, M., Abdoli, A., … Moradi Kalan, A. (2021). Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: A systematic analysis from the Global Burden of Disease Study 2019. The Lancet, 397(10292), 2337–2360.

Kalan Farmanfarma, K., Mahdavifar, N., Hassanipour, S., & Salehiniya, H. (2020). Epidemiologic study of gastric cancer in Iran: A systematic review. Clinical and Experimental Gastroenterology, 13, 511–542.

Kalan Farmanfarma, K., Mahdavifar, N., & Salehiniya, H. (2020). Bladder cancer in Iran: An epidemiological review. Research and Reports in Urology, 12, 91–103.

Alizadeh-Ghodsi, M., Zavvari, A., Ebrahimi-Kalan, A., Shiri-Shahsavar, M. R., & colleagues. (2018). The hypothetical roles of arsenic in multiple sclerosis by induction of inflammation and aggregation of tau protein: A commentary. Nutritional Neuroscience, 21(2), 92–96.

Shiri-Shahsavar, M. R., Mirshafiee, A., Parastouei, K., Ebrahimi-Kalan, A., & colleagues. (2016). A novel combination of docosahexaenoic acid, all-trans retinoic acid, and 1,25-dihydroxyvitamin D3 reduces T-bet gene expression and serum interferon levels. Journal of Molecular Neuroscience, 60(4), 498–508.

Ali Moradi Kalan’s research advances global oncology and public health by generating high-impact evidence on cancer burden, tobacco exposure, and population-level risk factors that directly inform prevention strategies and health policy. Through rigorous epidemiologic analyses and region-specific cancer studies, his work strengthens data-driven decision-making, supports equitable cancer control, and contributes to sustainable improvements in global health outcomes.